(3R,4R)-1-Benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride

We are (3R,4R)-1-Benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride CAS:1062580-52-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:   (3R,4R)-1-Benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride
CAS.NO:1062580-52-2
Synonyms:
cis-n-benzyl-3-methylamino-4-methyl-piperidine dihydrochloride
cis-n-benzyl-3-methylamino-4-methyl-piperidine bis(hydrochloride)

Molecular Formula: C14H24Cl2N2
Molecular Weight:291.26000

Physical and Chemical Properties:
Density: 1.56
Boiling point: 721.1ºC at 760 mmHg
Melting point: 219-220 ° C (lit.)
Flash point: 200 ° C
Refractive index: 1.590

Specification:
Appearance:white powder
Purity:≥98%
Water:≤0.5%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Tofacitinib CAS:477600-75-2
Intermediates of Tofacitinib citrate CAS:540737-29-9

Related News: The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).N-cyclohexyl-N'-(2-(4-morpholinyl)ethyl)carbodiimide The drug, Imfinzi, when added to chemotherapy and the drugmaker’s other cancer drug tremelimumab, significantly improved the survival of patients without the disease progressing, when compared to chemotherapy alone, the company said.Acetato de 8-yodo-1-octanol CAS:75415-20-2 The drug, Imfinzi, when added to chemotherapy and the drugmaker’s other cancer drug tremelimumab, significantly improved the survival of patients without the disease progressing, when compared to chemotherapy alone, the company said.1,1-Dichloropinacoline CAS:22591-21-5 The drug, Imfinzi, when added to chemotherapy and the drugmaker’s other cancer drug tremelimumab, significantly improved the survival of patients without the disease progressing, when compared to chemotherapy alone, the company said.The data will be updated at the upcoming 2019 ASH Annual Meeting next week.